

## Early and locally advanced breast cancer: diagnosis and management – radiotherapy dose fractionation (update)

NICE guideline: acknowledgments

*NICE guideline NG101*

*Authors and contributors*

*June 2023*

*Commissioned by the National Institute for  
Health and Care Excellence*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE 2023. All rights reserved. Subject to [Notice of rights](#).

# Contents

<b>1</b>	<b>Guideline developers .....</b>	<b>5</b>
1.1	Members of the NICE guideline committee:.....	5
1.2	Members of the NICE Guideline Development Team: .....	5
1.3	Members of the wider NICE Team: .....	5
1.4	Acknowledgements: .....	6

# 1 Guideline developers

## 1.1 Members of the NICE guideline committee:

Name	Role
Adam Firth	Committee Chair - GP Partner, Bracondale Medical Centre, Stockport
Josie Cameron	Committee member (Therapeutic Radiographer) - Breast Advanced Practitioner, NHS Lothian
Donna Egbeare	Committee member (Breast Surgeon) - Consultant Oncoplastic Surgeon and Clinical Service Lead for Breast Care, Torbay and South Devon NHS Foundation Trust
Nuala Healy	Committee member (Radiologist) - Clinical Breast Radiologist, Cambridge Breast Unit, Addenbrookes Hospital
Claire Kelly	Committee member (Clinical Oncologist) - Consultant Clinical Oncologist, The Christie NHS Foundation Trust
Tamsin Sargeant	Committee member (Lay Member)
Anita Sharma	Committee member (General Practitioner) - GP, South Chadderton Health Centre, Oldham
Katy Tan	Committee member (Lay Member)

## 1.2 Members of the NICE Guideline Development Team:

Name	Role
Omnia Bilal	Technical Analyst
Becky Chadwick	Project Manager
Lindsay Claxton	Technical Adviser – Health Economics
Danielle Conroy	Project Manager
Clare Dadswell	Senior Technical Analyst
Jacqueline Durkin	Administrator
Marie Harrisingh	Technical Adviser
Jean Ryan	Programme Manager
Kate Kelley	Associate Director
Yolanda Martinez	Technical Analyst
Natasha Salant	Technical Analyst - Health Economics
Fernando Zanghelini	Technical Analyst

## 1.3 Members of the wider NICE Team:

Name	Role
Jeremy Braybrooke	Consultant Clinical Adviser
Victoria Carter	Adoption and Implementation Manager
Gareth Haman	Senior Medical Editor
Kathryn Hopkins	Technical Adviser (QA)
Lesley Owen	Technical Adviser – Health Economics (QA)
Louisa Regan	Adoption and Implementation Manager
Sarah Scott	Public Involvement Adviser

Name	Role
Adam Storrow	Business Analyst - Resource Impact
Daniel Tuvey	Information Specialist
Nicola Walsh	Senior information Manager

## 1.4 Acknowledgements:

Thanks to the authors of the FAST-Forward trial on hypofractionated breast radiotherapy for 1 week versus 3 weeks, including David Glynn for generating additional economic analyses which was used in this work. See [Evidence Review M](#) for further details.